{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:01:48Z","timestamp":1785542508422,"version":"3.56.0"},"reference-count":50,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T00:00:00Z","timestamp":1742515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Plasma cell neoplasms include a spectrum of disorders, such as plasma cell leukemia (PCL) and light chain (AL) amyloidosis, all associated with poor prognosis and limited therapeutic options. Venetoclax is the first-in-class B-cell lymphoma 2 (BCL-2) inhibitor and triggers apoptosis selectively in cells reliant on the BCL-2 pathway for survival. Randomized clinical trials have established the anti-tumor activity and efficacy of venetoclax in selected patients with hematologic malignancies such as acute myeloid leukemia (AML), chronic lymphocytic leukemia (CLL), and multiple myeloma (MM). At the same time, recent studies suggest its potential application in rare plasma cell dyscrasias. Preliminary results from case reports and a small cohort of patients indicate that venetoclax may benefit patients with PCL. Regimens incorporating venetoclax have also demonstrated promising outcomes in patients with AL amyloidosis, particularly those with translocation (11;14). This review analyzes new data on venetoclax in AL amyloidosis and PCL and highlights the increasing significance of BCL-2 inhibition in plasma cell neoplasms beyond MM.<\/jats:p>","DOI":"10.3389\/fonc.2025.1549891","type":"journal-article","created":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T12:50:55Z","timestamp":1742561455000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":5,"title":["The potential role of BCL-2 inhibition in amyloidosis and plasma cell leukemia"],"prefix":"10.3389","volume":"15","author":[{"given":"Grigorios","family":"Alvanidis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Kotsos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christina","family":"Frouzaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amalia","family":"Fola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evdoxia","family":"Hatjiharissi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1513257","article-title":"Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia","volume":"374","author":"Roberts","year":"2016","journal-title":"N Engl J Med"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2213093","article-title":"First-line venetoclax combinations in chronic lymphocytic leukemia","volume":"388","author":"Eichhorst","year":"2023","journal-title":"N Engl J Med"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012971","article-title":"Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia","volume":"383","author":"DiNardo","year":"2020","journal-title":"N Engl J Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2017-06-788786","article-title":"Efficacy of venetoclax as targeted therapy for relapsed\/refractory t(11;14) multiple myeloma","volume":"130","author":"Kumar","year":"2017","journal-title":"Blood"},{"key":"B6","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1080\/13506129.2024.2366806","article-title":"Outcomes of venetoclax-based therapy in patients with t(11;14) light chain amyloidosis after failure of daratumumab-based therapy","volume":"31","author":"Dima","year":"2024","journal-title":"Amyloid"},{"key":"B7","doi-asserted-by":"publisher","first-page":"1610276","DOI":"10.3389\/pore.2022.1610276","article-title":"Targeted venetoclax therapy in t(11;14) multiple myeloma: real world data from seven hungarian centers","volume":"28","author":"Szita","year":"2022","journal-title":"Pathol Oncol Res"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.28415","article-title":"Systemic AL amyloidosis: current approach and future direction","volume":"14","author":"Bou Zerdan","year":"2023","journal-title":"Oncotarget"},{"key":"B9","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/s11912-019-0754-x","article-title":"Plasma cell leukemia: definition, presentation, and treatment","volume":"21","author":"Gundesen","year":"2019","journal-title":"Curr Oncol Rep"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.2991\/chi.k.200706.002","article-title":"Plasma cell leukemia - facts and controversies: more questions than answers","volume":"2","author":"Suska","year":"2020","journal-title":"Clin Hematol Int"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25331","article-title":"Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)","volume":"94","author":"Jelinek","year":"2019","journal-title":"Am J Hematol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/13506129.2020.1778461","article-title":"Presence of t(11;14) in AL amyloidosis as a marker of response when treated with a bortezomib-based regimen","volume":"27","author":"Dumas","year":"2020","journal-title":"Amyloid"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1016\/j.hoc.2020.08.001","article-title":"Systemic amyloidosis due to clonal plasma cell diseases","volume":"34","author":"Bianchi","year":"2020","journal-title":"Hematol Oncol Clin North Am"},{"key":"B14","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41572-018-0034-3","article-title":"Systemic immunoglobulin light chain amyloidosis","volume":"4","author":"Merlini","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27177","article-title":"Immunoglobulin light chain amyloidosis: 2024 update on diagnosis, prognosis, and treatment","volume":"99","author":"Gertz","year":"2024","journal-title":"Am J Hematol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1186\/s13023-022-02414-6","article-title":"Global epidemiology of amyloid light-chain amyloidosis","volume":"17","author":"Kumar","year":"2022","journal-title":"Orphanet J Rare Dis"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.21934","article-title":"Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk-stratification, and management","volume":"86","author":"Gertz","year":"2011","journal-title":"Am J Hematol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1056\/NEJMoa2028631","article-title":"Daratumumab-based treatment for immunoglobulin light-chain amyloidosis","volume":"385","author":"Kastritis","year":"2021","journal-title":"N Engl J Med"},{"key":"B19","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1186\/1750-1172-7-54","article-title":"Al amyloidosis","volume":"7","author":"Desport","year":"2012","journal-title":"Orphanet J Rare Dis"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.13369","article-title":"Translocation t(11;14) and survival of patients with light chain (AL) amyloidosis","volume":"94","author":"Bryce","year":"2009","journal-title":"Haematologica"},{"key":"B21","doi-asserted-by":"publisher","first-page":"1710","DOI":"10.3390\/cancers15061710","article-title":"Venetoclax in relapse\/refractory AL amyloidosis-A multicenter international retrospective real-world study","volume":"15","author":"Lebel","year":"2023","journal-title":"Cancers (Basel)"},{"key":"B22","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/01.HS9.0000936096.74708.86","article-title":"B01 venetoclax targeted therapy in al amyloidosis patients: a retrospective analysis from the french amyloidosis network","volume":"7","author":"Roussel","year":"2023","journal-title":"HemaSphere"},{"key":"B23","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41408-020-00397-w","article-title":"Venetoclax induces deep hematologic remissions in t(11;14) relapsed\/refractory AL amyloidosis","volume":"11","author":"Premkumar","year":"2021","journal-title":"Blood Cancer J"},{"key":"B24","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1038\/s41408-020-0321-6","article-title":"Venetoclax for the treatment of translocation (11;14) AL amyloidosis","volume":"10","author":"Sidiqi","year":"2020","journal-title":"Blood Cancer J"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-024-05901-x","article-title":"Three years follow-up of Venetoclax in advanced-stage, relapsed or refractory AL amyloidosis with cardiac involvement and t(11;14) with BCL2 expression","volume":"103","author":"Rieger","year":"2024","journal-title":"Ann Hematol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"2031","DOI":"10.1182\/blood-2023-183030","article-title":"Outcomes of venetoclax-based therapy in patients with daratumumab-refractory t(11;14) positive light chain amyloidosis","volume":"142","author":"Orland","year":"2023","journal-title":"Blood"},{"key":"B27","doi-asserted-by":"publisher","first-page":"e5544426","DOI":"10.1097\/01.HS9.0000975252.55444.26","article-title":"Pb2122: A phase 1\/2 multi-center, dose-finding study investigating the safety, tolerability, pk and efficacy of Zn-d5, a novel bcl-2 inhibitor, in patients with relapsed\/refractory Al amyloidosis","volume":"7","author":"Kastritis","year":"2023","journal-title":"HemaSphere"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90942-9","article-title":"Plasma cell leukemia: an evaluation of response to therapy","volume":"83","author":"Noel","year":"1987","journal-title":"Am J Med"},{"key":"B29","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1038\/s41408-021-00587-0","article-title":"Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage","volume":"11","author":"Fern\u00e1ndez de Larrea","year":"2021","journal-title":"Blood Cancer J"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-05-408682","article-title":"How I treat plasma cell leukemia","volume":"120","author":"van de Donk","year":"2012","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1016\/j.exphem.2018.02.002","article-title":"Venetoclax: A new wave in hematooncology","volume":"61","author":"Mihalyova","year":"2018","journal-title":"Exp Hematol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1111\/ejh.2018.100.issue-2","article-title":"Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)","volume":"100","author":"Gonsalves","year":"2018","journal-title":"Eur J Haematol"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.25676","article-title":"The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia","volume":"95","author":"Nalghranyan","year":"2020","journal-title":"Am J Hematol"},{"key":"B34","doi-asserted-by":"publisher","first-page":"8823877","DOI":"10.1155\/2020\/8823877","article-title":"Efficacy of venetoclax and dexamethasone in refractory igM primary plasma cell leukemia with t(11;14) and TP53 mutation: A case report and literature review","volume":"2020","author":"Valliani","year":"2020","journal-title":"Case Rep Hematol"},{"key":"B35","doi-asserted-by":"publisher","first-page":"e938868","DOI":"10.12659\/AJCR.938868","article-title":"Plasma cell leukemia with successful upfront venetoclax in combination with allogeneic transplantation","volume":"24","author":"Tang","year":"2023","journal-title":"Am J Case Rep"},{"key":"B36","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.1080\/10428194.2024.2381647","article-title":"Venetoclax-based induction therapy for primary plasma cell leukemia with high BCL-2 expression","volume":"65","author":"Charalampous","year":"2024","journal-title":"Leuk Lymphoma"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1177\/10781552221074269","article-title":"Complete response following treatment of plasma cell leukemia with venetoclax and dexamethasone: A case report","volume":"28","author":"Vo","year":"2022","journal-title":"J Oncol Pharm Pract"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2021.2010065","article-title":"Venetoclax in upfront induction therapy for primary plasma cell leukemia with t(11;14) or BCL2 expression","volume":"63","author":"Roy","year":"2022","journal-title":"Leuk Lymphoma"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.12998\/wjcc.v9.i5.1175","article-title":"Venetoclax in combination with chidamide and dexamethasone in relapsed\/refractory primary plasma cell leukemia without t(11;14): A case report","volume":"9","author":"Yang","year":"2021","journal-title":"World J Clin Cases"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1177\/1078155219895072","article-title":"A successful case of venetoclax-based therapy in relapsed\/refractory secondary plasma cell leukemia","volume":"26","author":"Kupsh","year":"2020","journal-title":"J Oncol Pharm Pract"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.v190.4","article-title":"Secondary plasma cell leukaemia treated with single agent venetoclax","volume":"190","author":"Glavey","year":"2020","journal-title":"Br J Haematol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1390747","DOI":"10.3389\/fonc.2024.1390747","article-title":"Venetoclax in the treatment of secondary plasma cell leukemia with translocation t(11;14): a case report and literature review","volume":"14","author":"Elsabah","year":"2024","journal-title":"Front Oncol"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2020-238641","article-title":"Plasma cell leukaemia with t(11;14) not responsive to venetoclax","volume":"14","author":"Abu Zaanona","year":"2021","journal-title":"BMJ Case Rep"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2023.283472","article-title":"Venetoclax salvage therapy in relapsed\/refractory multiple myeloma","volume":"109","author":"Steinhardt","year":"2024","journal-title":"Haematologica"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30525-8","article-title":"Venetoclax or placebo in combination with bortezomib and dexamethasone in patients with relapsed or refractory multiple myeloma (BELLINI): a randomised, double-blind, multicentre, phase 3 trial","volume":"21","author":"Kumar","year":"2020","journal-title":"Lancet Oncol"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.v102.6","article-title":"Moving beyond maximum tolerated dose for targeted oncology drugs: use of clinical utility index to optimize venetoclax dosage in multiple myeloma patients","volume":"102","author":"Freise","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"B47","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1186\/s12885-023-11553-3","article-title":"Efficacy and safety of venetoclax in patients with relapsed\/refractory multiple myeloma: a meta-analysis","volume":"23","author":"Gao","year":"2023","journal-title":"BMC Cancer"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26060","article-title":"Incidence of tumor lysis syndrome in patients with acute myeloid leukemia undergoing low-intensity induction with venetoclax","volume":"96","author":"Diao","year":"2021","journal-title":"Am J Hematol"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-0361","article-title":"Tumor lysis, adverse events, and dose adjustments in 297 venetoclax-treated CLL patients in routine clinical practice","volume":"25","author":"Roeker","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2023.2186480","article-title":"Efficacy and safety of Venetoclax-based regimens in relapsed or refractory multiple myeloma: a systematic review and meta-analysis of prospective clinical trials","volume":"55","author":"He","year":"2023","journal-title":"Ann Med"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1549891\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,21]],"date-time":"2025-03-21T12:50:57Z","timestamp":1742561457000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2025.1549891\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,21]]},"references-count":50,"alternative-id":["10.3389\/fonc.2025.1549891"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2025.1549891","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,21]]},"article-number":"1549891"}}